Search Results

There are 2995 results for: content related to: Treatment of upper-extremity deep vein thrombosis

  1. You have free access to this content
    A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 5, May 2012, Pages: 833–839, S. W. RATHBUN, C. E. ASTON and T. L. WHITSETT

    Version of Record online : 2 MAY 2012, DOI: 10.1111/j.1538-7836.2012.04669.x

  2. Dalteparin dose-dependently increases ROTEM® thrombelastography parameters only at supratherapeutic anti-factor Xa levels: An in vitro study

    Clinical and Experimental Pharmacology and Physiology

    Volume 38, Issue 11, November 2011, Pages: 783–786, Martin Feuring, Martin Wehling and Armin Schultz

    Version of Record online : 20 OCT 2011, DOI: 10.1111/j.1440-1681.2011.05593.x

  3. Safety of Outpatient Dalteparin Therapy in Veterans with Mechanical Heart Valves

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 25, Issue 11, November 2005, Pages: 1560–1565, Jessica L. O'Neill, Petra S. Flanagan, Carolyn R. Zaleon and Laurel A. Copeland

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.2005.25.11.1560

  4. Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy

    Pediatric Blood & Cancer

    Volume 55, Issue 6, 1 December 2010, Pages: 1118–1125, Hirotoshi Sakaguchi, Nobuhiro Watanabe, Hideki Muramatsu, Sayoko Doisaki, Nao Yoshida, Kimikazu Matsumoto and Koji Kato

    Version of Record online : 29 JUN 2010, DOI: 10.1002/pbc.22645

  5. You have free access to this content
    In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time

    Veterinary Clinical Pathology

    Volume 37, Issue 4, December 2008, Pages: 363–372, Lisbeth R. Jessen, Bo Wiinberg, Asger L. Jensen, Mads Kjelgaard-Hansen, Kate H. Jensen, Lotte B. Pedersen and Annemarie T. Kristensen

    Version of Record online : 27 AUG 2008, DOI: 10.1111/j.1939-165X.2008.00068.x

  6. Life-Threatening Hemorrhage After Dalteparin Therapy in a Patient with Impaired Renal Function

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 25, Issue 6, June 2005, Pages: 881–885, Ms. Sabin S. Egger, Dr. Mikael G. Sawatzki, Dr. Jürgen Drewe and Dr. Stephan Krähenbühl

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.2005.25.6.881

  7. You have free access to this content
    Abstracts

    Journal of Thrombosis and Haemostasis

    Volume 3, Issue s1, August 2005, Pages: P0001–P2386,

    Version of Record online : 9 SEP 2013, DOI: 10.1111/j.1538-7836.2005.0300c.x

  8. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin

    International Journal of Gynecology & Obstetrics

    Volume 71, Issue 1, October 2000, Pages: 19–24, E. Rey and G.E. Rivard

    Version of Record online : 19 OCT 2000, DOI: 10.1016/S0020-7292(00)00290-3

  9. You have free access to this content
    Abstracts

    Journal of Thrombosis and Haemostasis

    Volume 3, Issue s1, August 2005, Pages: H01–SYM90,

    Version of Record online : 6 SEP 2013, DOI: 10.1111/j.1538-7836.2005.03000.x

  10. You have free access to this content
    The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study

    Clinical Cardiology

    Volume 24, Issue S1, March 2001, Pages: 12–14, Lars Wallentin, B. Lindahl, M. Dellborg, T. Nilsson, K. Pehrsson and E. Swahn

    Version of Record online : 3 FEB 2009, DOI: 10.1002/clc.4960241305

  11. You have free access to this content
    Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement

    Journal of Thrombosis and Haemostasis

    Volume 1, Issue 5, May 2003, Pages: 896–906, O. E. Dahl and A. M. Pleil

    Version of Record online : 25 APR 2003, DOI: 10.1046/j.1538-7836.2003.00236.x

  12. Clinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin

    Journal of Veterinary Emergency and Critical Care

    Volume 24, Issue 4, July/August 2014, Pages: 421–428, Alex M. Lynch, Armelle M. deLaforcade and Claire R. Sharp

    Version of Record online : 22 AUG 2014, DOI: 10.1111/vec.12206

  13. You have free access to this content
    Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease

    Journal of Internal Medicine

    Volume 258, Issue 5, November 2005, Pages: 420–427, J. OLDGREN, C. FELLENIUS, K. BOMAN, J.-H. JANSSON, T. K. NILSSON, L. WALLENTIN and A. SIEGBAHN

    Version of Record online : 17 OCT 2005, DOI: 10.1111/j.1365-2796.2005.01562.x

  14. You have full text access to this OnlineOpen article
    Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo

    APMIS

    Volume 118, Issue 12, December 2010, Pages: 949–957, KLAS NORRBY and ARVID NORDENHEM

    Version of Record online : 12 OCT 2010, DOI: 10.1111/j.1600-0463.2010.02635.x

  15. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

    Intervention Review

    The Cochrane Library

    Marcello Di Nisio, Ettore Porreca, Matteo Candeloro, Michele De Tursi, Ilaria Russi and Anne WS Rutjes

    Published Online : 1 DEC 2016, DOI: 10.1002/14651858.CD008500.pub4

  16. You have free access to this content
    A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I

    Journal of Thrombosis and Haemostasis

    Volume 1, Issue 1, January 2003, Pages: 41–47, H. Eriksson, K. Wåhlander, D. Gustafsson, L.t Welin, L. Frison, S. Schulman and for the thrive investigators

    Version of Record online : 3 JAN 2003, DOI: 10.1046/j.1538-7836.2003.00034.x

  17. You have free access to this content
    A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease

    Clinical Cardiology

    Volume 24, Issue 7, July 2001, Pages: 492–499, Steen Husted, Richard Becker and Andre Kher

    Version of Record online : 3 FEB 2009, DOI: 10.1002/clc.4960240715

  18. You have free access to this content
    Improving outcomes in acute coronary syndromes—The FRISCII trial

    Clinical Cardiology

    Volume 24, Issue S1, March 2001, Pages: 3–7, Frederic Kontny

    Version of Record online : 3 FEB 2009, DOI: 10.1002/clc.4960241303

  19. You have free access to this content
    Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial

    Journal of Thrombosis and Haemostasis

    Volume 7, Issue 1, January 2009, Pages: 58–64, E. REY, P. GARNEAU, M. DAVID, R. GAUTHIER, L. LEDUC, N. MICHON, F. MORIN, C. DEMERS, S. R. KAHN, L. A. MAGEE and M. RODGER

    Version of Record online : 20 NOV 2008, DOI: 10.1111/j.1538-7836.2008.03230.x

  20. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

    Journal of Internal Medicine

    Volume 240, Issue 2, August 1996, Pages: 85–92, K. LUOMANMÄKI, S. GRANKVIST, C. HALLERT, I. JAURO, K. KETOLA, H. C. KIM, H. KIVINIEMI, H. KOSKIVIRTA, L. SÖRSKOG and P. VILKKO

    Version of Record online : 31 OCT 2003, DOI: 10.1046/j.1365-2796.1996.18845000.x